ashg

AKESOgen delegates attend and present at ASHG in Vancouver

vancouver

AKESOgen exhibited and presented at the American Society of Human Genetics 2016 Annual Meeting in Vancouver, Canada, October 18th – 22nd.

Dr. Bouzyk presented novel genotyping solutions for large scale genotyping studies. We invite you learn more about our genomics solutions in:

  • Research Services
  • Clinical Diagnostics Services
  • Clinical Trials Services

by contacting us at 770 542 0890 or emailing mcooke@akesogen.com

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
AKESOgen

For the Second Consecutive Year AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

AKESOgen Ranks as the No. 23 Healthcare Company and 240th Overall on the 2016 Inc.500 with Three-Year Sales Growth of 1,615%

 

NEW YORK and ATLANTA August 17, 2016Inc. magazine today ranked AKESOgen, 23rd as a Healthcare company and 240th overall on its 35th annual Inc. 500, the most prestigious ranking of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment— its independent small businesses. Companies such as Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names gained their first national exposure as honorees of the Inc. 500|5000.

“Once again, we are delighted to be recognized for the second consecutive year as an Inc.500 honoree with such well known organizations in 2016 as Square, Dollar Shave Club, ipsy and Yeti Cooler.” commented AKESOgen CEO Robert Boisjoli.

“We are fortunate to be in a business which is at the forefront of providing the latest molecular technologies for 21st century personalized medicine. The knowledge and impact of DNA and our own genetic makeup is becoming more and more a part of our everyday lives and will only continue to increase. AKESOgen is providing new cutting edge genomic tools and services to enable this emerging approach to science.” says Mark Bouzyk, PhD, AKESOgen’s Chief Scientific Officer.

The 2016 Inc. 5000, unveiled online at Inc.com and with the top 500 companies featured in the September issue of Inc. (available on newsstands August 23) is the most competitive crop in the list’s history. The average company on the list achieved a mind-boggling three-year growth of 433%. The Inc. 5000’s aggregate revenue is $200 billion, and the companies on the list collectively generated 640,000 jobs over the past three years, or about 8% of all jobs created in the entire economy during that period. Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.

“The Inc. 5000 list stands out where it really counts,” says Inc. President and Editor-In-Chief Eric Schurenberg. “It honors real achievement by a founder or a team of them. No one makes the Inc. 5000 without building something great – usually from scratch. That’s one of the hardest things to do in business, as every company founder knows. But without it, free enterprise fails.”

 About Inc. Media:

Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders. Winner of the National Magazine Award for General Excellence in both 2014 and 2012. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 15,000,000 today.  For more information, visit www.inc.com.

For more information contact:

Inc. Media

Drew Kerr

212-849-8250

drew@four-corners.com

 About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

Media Contact:

Marissa Cooke, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890, or mcooke@akesogen.com

 

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
Cancer Research Wales

Dr. Mark Bouzyk Speaks as Keynote at the 50th anniversary of Cancer Research Wales, Ymchwil Canser Cymru

Dr. Mark Bouzyk, CSO of AKESOgen, spoke at SWALEC stadium in Cardiff, U.K for the Cancer Research Wales 50th anniversary. March 1st commemorates St. David’s day, a national day of celebration within Wales. Cancer Research Wales showcased its milestones and research achievements over the last 50 years. The theme of the symposium was “Cancer Research Wales at 50 Working Towards Precision Medicine.” The symposium brought together top cancer scientists and clinicians from across Wales and the UK giving them an opportunity to discuss and share their latest findings but also plan future collaborations.

Mark Bouzyk Cancer Research Wales

Mark Bouzyk Cancer Research Wales

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
cancer research Wales

Dr. Mark Bouzyk to Keynote at the 50th anniversary of Cancer Research Wales, Ymchwil Canser Cymru

March 1st, 2016 – Dr. Mark Bouzyk, CSO of AKESOgen, has been invited to the SWALEC stadium in Cardiff, U.K for the Cancer Research Wales 50th anniversary.   March 1st commemorates St. David’s day, a national day of celebration within Wales. Cancer Research Wales will be showcasing its milestones and research achievements over the last 50 years with the theme of the symposium is “Cancer Research Wales at 50 Working Towards Precision Medicine.”  The symposium will bring together top cancer scientists and clinicians from across Wales and the UK giving them an opportunity to discuss and share their latest findings but also plan future collaborations.

 

Cancer Research WalesAKESOgen-Logo333

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
CAP

AKESOgen Receives Accreditation from College of American Pathologists

CAP 2

Atlanta, GA – 8th February 2016 – Personalized Medicine and genomics company AKESOgen, announced today Accreditation from the College of American Pathologists (CAP).

The AKESOgen facility in Atlanta completed a comprehensive on-site inspection and analysis of its oncology testing as part of the CAP’s Accreditation Programs. The CAP Laboratory Accreditation Program involves a process of inspections of clinical lab records and quality control procedures and assessments of a lab’s staff qualifications, equipment, facilities, safety program, and overall management.

“This is an important endorsement by the College of American Pathologists for AKESOgen to provide our comprehensive cytogenomics oncology tests and services for a wide spectrum of solid and liquid tumors and will be of particular benefit to patients –as the tests are offered as a complement to NGS clinical oncology testing,” commented Gabriela M. Oprea, MD, the facility’s director.

“AKESOgen is honored to achieve accreditation from the College of American Pathologists. CAP accreditation is viewed as the ‘crème de la crème’ for laboratory testing. The whole team at AKESOgen is proud to be awarded this prestigious accreditation. This achievement strengthens our commitment to enabling Precision Medicine at the highest quality possible,” said Dr Mark Bouzyk, CSO of AKESOgen.

 About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput biomarker profiling, cytogenetic arrays, sequencing, and genomics analyses utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

About the College of American Pathologists

As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP’s Laboratory Improvement Programs, initiated 65 years ago, currently have customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at www.cap.org. Follow CAP on Twitter: @pathologists.

Media Contact:

Marissa Cooke, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890 or mcooke@akesogen.com

CAP-logo-750x456

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Brian Leyland-Jones, Kathryn P. Gray, Mark Abramovitz, Mark Bouzyk, Brandon Young, Bradley Long, Roswitha Kammler, Patrizia Dell’Orto, Beat Thürlimann, Vernon Harvey, Patrick Neven, Laurent Arnould, Rudolf Maibach, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani, Giuseppe Viale, James M. Rae and Meredith M. Regan; on behalf of the BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail